Literature DB >> 22025363

Codon usage roles in human papillomavirus.

Kong-Nan Zhao1, Jiezhong Chen.   

Abstract

Human papillomavirus (HPV) genomes, similar to other virus genomes, frequently have a G + C content significantly different from their host species. The HPV genomes show a strong codon usage bias to 18 codons, with 14 showing T at the third position amongst degenerately encoded amino acids. The codon usage pattern in HPV genome plays an important role, which regulates low or non-translational expression of the viral capsid genes and results in very weak protein expression of oncogenes in a wide range of mammalian cells. Codon modification has been proved to be a powerful technology to overcome the translational blockage and weak expression of both HPV capsid genes and oncogenes in different expression systems. Furthermore, keratinocytes are the host cells of HPV infection; the codon usage in HPV capsid genes matches available aminoacyl-tRNAs in differentiated keratinocytes to modulate their protein expression. HPV DNA vaccines with codon optimization have been shown to have higher immunogenicity and induce both strong cellular and humoral responses in animal models, which may be a promising form of therapeutic HPV vaccines.
Copyright © 2011 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22025363     DOI: 10.1002/rmv.707

Source DB:  PubMed          Journal:  Rev Med Virol        ISSN: 1052-9276            Impact factor:   6.989


  15 in total

Review 1.  Roles of the PI3K/Akt pathway in Epstein-Barr virus-induced cancers and therapeutic implications.

Authors:  Jiezhong Chen
Journal:  World J Virol       Date:  2012-12-12

2.  Selective pressure dominates the synonymous codon usage in parvoviridae.

Authors:  Sheng-Lin Shi; Yi-Ren Jiang; Yan-Qun Liu; Run-Xi Xia; Li Qin
Journal:  Virus Genes       Date:  2012-09-21       Impact factor: 2.332

3.  Hepatitis A virus adaptation to cellular shutoff is driven by dynamic adjustments of codon usage and results in the selection of populations with altered capsids.

Authors:  M Isabel Costafreda; Francisco J Pérez-Rodriguez; Lucía D'Andrea; Susana Guix; Enric Ribes; Albert Bosch; Rosa M Pintó
Journal:  J Virol       Date:  2014-02-19       Impact factor: 5.103

4.  Rare codons regulate KRas oncogenesis.

Authors:  Benjamin L Lampson; Nicole L K Pershing; Joseph A Prinz; Joshua R Lacsina; William F Marzluff; Christopher V Nicchitta; David M MacAlpine; Christopher M Counter
Journal:  Curr Biol       Date:  2012-12-13       Impact factor: 10.834

Review 5.  HPV-p53-miR-34a axis in HPV-associated cancers.

Authors:  Jiezhong Chen; Kong-Nan Zhao
Journal:  Ann Transl Med       Date:  2015-12

6.  Enhanced therapeutic efficacy of Listeria-based cancer vaccine with codon-optimized HPV16 E7.

Authors:  Feifei Duan; Jiaqi Chen; Hao Yao; Yuting Wang; Yanyan Jia; Zhiting Ling; Youwei Feng; Zhiming Pan; Yuelan Yin; Xin'An Jiao
Journal:  Hum Vaccin Immunother       Date:  2021-01-15       Impact factor: 3.452

Review 7.  The role of the PI3K/Akt/mTOR signalling pathway in human cancers induced by infection with human papillomaviruses.

Authors:  Lifang Zhang; Jianhong Wu; Ming Tat Ling; Liang Zhao; Kong-Nan Zhao
Journal:  Mol Cancer       Date:  2015-04-17       Impact factor: 27.401

8.  Characterization and whole genome analysis of human papillomavirus type 16 e1-1374^63nt variants.

Authors:  Ivan Sabol; Mihaela Matovina; Ali Si-Mohamed; Magdalena Grce
Journal:  PLoS One       Date:  2012-07-24       Impact factor: 3.240

9.  Vaccinia and influenza A viruses select rather than adjust tRNAs to optimize translation.

Authors:  Mariana Pavon-Eternod; Alexandre David; Kimberly Dittmar; Peter Berglund; Tao Pan; Jack R Bennink; Jonathan W Yewdell
Journal:  Nucleic Acids Res       Date:  2012-12-18       Impact factor: 16.971

10.  The invisible enemy - how human papillomaviruses avoid recognition and clearance by the host immune system.

Authors:  Agnieszka K Grabowska; Angelika B Riemer
Journal:  Open Virol J       Date:  2012-12-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.